Dr Alireza Nikbaksh Tehrani, DO | |
19341 Bear Valley Rd, Suite 205, Apple Valley, CA 92308-5151 | |
(760) 240-2444 | |
Not Available |
Full Name | Dr Alireza Nikbaksh Tehrani |
---|---|
Gender | Male |
Speciality | Plastic And Reconstructive Surgery |
Experience | 22 Years |
Location | 19341 Bear Valley Rd, Apple Valley, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588816425 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | OS012696 (Pennsylvania) | Secondary |
208200000X | Plastic Surgery | 20A10839 (California) | Primary |
Entity Name | Alireza Tehrani Do Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1033444229 PECOS PAC ID: 7416098231 Enrollment ID: O20091230000498 |
News Archive
We regularly find ourselves in situations in which we talk to others. We talk to friends in a different way than we do to strangers. One important skill for this is not just understanding what the other person is saying but also recognizing who is talking.
A robotic wheelchair is being developed that will help children learn to 'drive'. Researchers writing in BioMed Central's open access Journal of NeuroEngineering and Rehabilitation describe the testing of ROLY -RObot-assisted Learning for Young drivers - in a group of children without disabilities and one child with cerebral palsy.
Today, a state court denied eight retail pharmacies' motion to stop the ten percent Medi-Cal provider cuts. The pharmacies sought a temporary restraining order (TRO) from Sacramento Superior Court against the California Department of Health Care Services and its director Sandra Shewry to block the cuts from being implemented.
QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Alireza Nikbaksh Tehrani, DO 17868 Us Highway 18, #357, Apple Valley, CA 92307-1267 Ph: (760) 927-2002 | Dr Alireza Nikbaksh Tehrani, DO 19341 Bear Valley Rd, Suite 205, Apple Valley, CA 92308-5151 Ph: (760) 240-2444 |
News Archive
We regularly find ourselves in situations in which we talk to others. We talk to friends in a different way than we do to strangers. One important skill for this is not just understanding what the other person is saying but also recognizing who is talking.
A robotic wheelchair is being developed that will help children learn to 'drive'. Researchers writing in BioMed Central's open access Journal of NeuroEngineering and Rehabilitation describe the testing of ROLY -RObot-assisted Learning for Young drivers - in a group of children without disabilities and one child with cerebral palsy.
Today, a state court denied eight retail pharmacies' motion to stop the ten percent Medi-Cal provider cuts. The pharmacies sought a temporary restraining order (TRO) from Sacramento Superior Court against the California Department of Health Care Services and its director Sandra Shewry to block the cuts from being implemented.
QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting tendency of blood while on medication) below a certain level within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma (a localized swelling filled with blood) enlargement, and resumption of anticoagulant therapy was associated with a lower risk of ischemic events without increased bleeding complications, according to a study in the February 24 issue of JAMA.
› Verified 2 days ago